Basic Information
| LncRNA/CircRNA Name | lncKLHDC7B |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | effector cells, immunosuppressive cells,MHC molecules, and selected immunomodulators | Survival | ||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, etc. |
| Sample | breast cancer tissues, MCF10A, BT20, MDA-MB-468, MDA-MB-231, Hs578-T, MCF-7, and HCC1187 cell lines |
| Expression Pattern | differentially expressed |
| Function Description | LncKLHDC7B (ENSG00000226738) acts as a transcriptional modulator of its neighboring coding gene KLHDC7B in the immunomodulatory subtype. Furthermore, LncKLHDC7B knockdown enhanced migration and invasion, and promoted resistance to cellular death. Our findings confirmed the contribution of LncKLHDC7B to induction of apoptosis and inhibition of cell migration and invasion, suggesting that TNBC tumors with enrichment of LncKLHDC7B may exhibit distinct regulatory activity, or that this may be a generalized process in breast cancer. Additionally, in silico analysis confirmed for the first time that the low expression of KLHDC7B and LncKLHDC7B is associated with poor prognosis in patients with breast cancer. |
| Pubmed ID | 30648789 |
| Year | 2019 |
| Title | Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death |
External Links
| Links for lncKLHDC7B | GenBank HGNC NONCODE |
| Links for Triple negative breast cancer | OMIM COSMIC |